Literature DB >> 27600177

Resistant Hypertension: Insights on Evaluation and Management in the Post-SPRINT (Systolic Blood Pressure Intervention Trial) Era.

Raymond R Townsend1, Murray Epstein2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27600177     DOI： 10.1161/HYPERTENSIONAHA.116.07316

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  5 in total

1.  [Therapy-resistant and therapy-refractory arterial hypertension].

Authors:  M Wallbach; M J Koziolek
Journal:  Internist (Berl)       Date:  2018-06       Impact factor: 0.743

2.  Eplerenone-Resistant Salt-Sensitive Hypertension in Nedd4-2 C2 KO Mice.

Authors:  Tabito Kino; Tomoaki Ishigami; Tsumugi Murata; Hiroshi Doi; Rie Nakashima-Sasaki; Lin Chen; Michiko Sugiyama; Kengo Azushima; Hiromichi Wakui; Shintaro Minegishi; Kouichi Tamura
Journal:  Int J Mol Sci       Date:  2017-06-11       Impact factor: 5.923

3.  Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study.

Authors:  Donghao Zhou; Bo Xi; Min Zhao; Liang Wang; Sreenivas P Veeranki
Journal:  Sci Rep       Date:  2018-06-20       Impact factor: 4.379

4.  Intensive Blood Pressure Treatment for Resistant Hypertension.

Authors:  Tetsuro Tsujimoto; Hiroshi Kajio
Journal:  Hypertension       Date:  2019-02       Impact factor: 10.190

5.  Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure.

Authors:  Patrick Rossignol; Bryan Williams; Martha R Mayo; Suzette Warren; Susan Arthur; Gail Ackourey; William B White; Rajiv Agarwal
Journal:  Eur J Heart Fail       Date:  2020-05-25       Impact factor: 15.534
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.